ArriVent BioPharma, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
AVBP Nasdaq 2836 arrivent.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for ArriVent BioPharma, Inc.

We Think ArriVent BioPharma (NASDAQ:AVBP) Needs To Drive Business Growth Carefully - Nov 12th, 2025 3:34 am
ArriVent BioPharma Reports Third Quarter 2025 Financial Results - Nov 10th, 2025 6:00 am
ArriVent Appoints Brent S. Rice as Chief Commercial Officer - Sep 22nd, 2025 2:05 pm
Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer - Sep 9th, 2025 6:00 am
ArriVent BioPharma Reports Second Quarter 2025 Financial Results - Aug 11th, 2025 6:00 am
ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026 - Jul 21st, 2025 6:00 am
New Strong Sell Stocks for July 21st - Jul 21st, 2025 4:08 am
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Wednesday Ahead of Looming Tariff Deadline - Jul 2nd, 2025 6:40 am
ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants - Jul 1st, 2025 9:15 pm
ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants - Jul 1st, 2025 2:05 pm
ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study - Jun 23rd, 2025 5:00 am
ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC - Jun 20th, 2025 2:05 pm
Is ArriVent BioPharma (NASDAQ:AVBP) In A Good Position To Deliver On Growth Plans? - May 14th, 2025 5:11 am
ArriVent BioPharma Reports First Quarter 2025 Financial Results - May 12th, 2025 6:00 am
ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors - Apr 28th, 2025 6:00 am
ArriVent BioPharma (AVBP): Among the Best Short Squeeze Stocks to Buy According to Analysts - Mar 19th, 2025 2:23 pm
ArriVent BioPharma Reports Full Year 2024 Financial Results - Mar 3rd, 2025 5:00 am
ArriVent Biopharma price target raised to $39 from $36 at H.C. Wainwright - Jan 23rd, 2025 5:05 am
ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers - Jan 21st, 2025 5:00 pm